Literature DB >> 17507116

Pathophysiology of cancer cachexia: much more than host-tumour interaction?

Richard J E Skipworth1, Grant D Stewart, Cornelis H C Dejong, Tom Preston, Kenneth C H Fearon.   

Abstract

Cancer cachexia is a syndrome of progressive nutritional depletion which causes significant morbidity and mortality in cancer patients. One of the main pathogenetic mechanisms underlying cancer cachexia is a complex interaction between the host and the tumour. Tumour cells interact with host cells within the tumour mass resulting in the production of catabolic mediators which degrade host tissue. In addition, the host may mount an aberrant metabolic response to the tumour. However, in recent years, it has also been understood that patient factors, including age and levels of physical activity, and the specific mechanics of protein metabolism in cancer patients may also have a significant impact. In this review article, we not only summarise previous knowledge surrounding host-tumour interaction, but we also discuss these broader concepts in the pathogenesis of cancer cachexia. Clinicians should consider such concepts in the design of an effective multimodal therapy for cachexia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507116     DOI: 10.1016/j.clnu.2007.03.011

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  48 in total

1.  Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).

Authors:  Shun Sasaki; Eiji Oki; Hiroshi Saeki; Takayuki Shimose; Sanae Sakamoto; Qingjiang Hu; Kensuke Kudo; Yasuo Tsuda; Yuichiro Nakashima; Koji Ando; Yoshito Akagi; Yoshihiro Kakeji; Hideo Baba; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2019-05-06       Impact factor: 3.402

2.  Cachexia has only one meaning.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2007-07-03       Impact factor: 4.599

3.  Prevalence and influence of malnutrition on quality of life and performance status in patients with locally advanced head and neck cancer before treatment.

Authors:  Giorgio Capuano; Pier Carlo Gentile; Federico Bianciardi; Michela Tosti; Anna Palladino; Mario Di Palma
Journal:  Support Care Cancer       Date:  2009-06-29       Impact factor: 3.603

4.  Hilar and mediastinal sarcoid-like reaction after the treatment of malignant tumors: imaging features and natural course on 18F-FDG-PET/CT.

Authors:  Yo Kaneko; Hiroki Kato; Masayuki Matsuo
Journal:  Jpn J Radiol       Date:  2018-10-15       Impact factor: 2.374

Review 5.  Tumors as organs: complex tissues that interface with the entire organism.

Authors:  Mikala Egeblad; Elizabeth S Nakasone; Zena Werb
Journal:  Dev Cell       Date:  2010-06-15       Impact factor: 12.270

6.  PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia.

Authors:  Fabrizio Pin; Leah J Novinger; Joshua R Huot; Robert A Harris; Marion E Couch; Thomas M O'Connell; Andrea Bonetto
Journal:  FASEB J       Date:  2019-03-20       Impact factor: 5.191

7.  Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival.

Authors:  Relin Yang; Michael C Cheung; Felipe E Pedroso; Margaret M Byrne; Leonidas G Koniaris; Teresa A Zimmers
Journal:  J Surg Res       Date:  2011-05-23       Impact factor: 2.192

8.  Proteomic identification of potential markers of myosteatosis in human urine.

Authors:  Holger Husi; Alisdair MacDonald; Richard J E Skipworth; Janice Miller; Andrew Cronshaw; Kenneth C H Fearon; James A Ross
Journal:  Biomed Rep       Date:  2018-04-25

Review 9.  Cachexia in patients with oesophageal cancer.

Authors:  Poorna Anandavadivelan; Pernilla Lagergren
Journal:  Nat Rev Clin Oncol       Date:  2015-11-17       Impact factor: 66.675

Review 10.  Inflammatory burden and amino acid metabolism in cancer cachexia.

Authors:  William J Durham; Edgar Lichar Dillon; Melinda Sheffield-Moore
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2009-01       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.